Devicare launches Canoxidin®
Devicare, a company located at the UAB Research Park, launches Canoxidin®, the only product in the market that avoids the complications derived from the use of urology dispositives, such as bladder catheters, ureteral catheters, or nephrostomy tubes.
Canoxidin® is a first-in-class oral treatment that will allow all Spanish urologists to reduce the calcification risk in urology dispositives up to 8 times, according to the results from Torrecilla et al., 2020, published at BMC Urology. It is a patented product with clinical evidence, and, besides Spain, it is also commercialised in the Netherlands and Malta.
This project finally sees the light after a long way of development and clinical research in which to date more than 10 hospitals have taken part, as well as more than 20 urologists. Their results have obtained a great deal of clinical interest, being presented in more than 15 international scientific congresses and published in three high-impact publications.
“At Devicare, we are aware of the importance for both the urologist and their patient to avoid the urology dispositives to calcify. For this reason, we believe that Canoxidin® will revolutionise the way of treating all of the patients that find themselves in these situations," says Marc Sendra, Product Manager at Devicare.
According to Rosendo Garganta, CEO at Devicare: “Canoxidin® is another step with our compromise with urology to research, develop, and bring to the market innovative products that can cover medical necessities not covered. The development of Canoxidin® is especially relevant in this compromise because it is the result of the collaboration of many Spanish urologists led by Dr. Carlos Torrecilla from the Hospital de Bellvitge and represents an international disruption in the treatment of patients carrying urology dispositives”.